ReGen Factor to Seek FDA Approval for Groundbreaking Diabetic Ulcer Treatment Utilizing Bio-Identical Fibroblast Growth Factor (bFGF)

FOR IMMEDIATE RELEASE

ReGen Factor to Seek FDA Approval for Groundbreaking Diabetic Ulcer Treatment Utilizing Bio-Identical Fibroblast Growth Factor (bFGF)

Australia – August 1, 2024 – ReGen Factor, a leading Australia-based biotechnology company specializing in bio-identical fibroblast growth factors (FGFs), proudly announces its plans to seek FDA approval for its revolutionary treatment targeting diabetic ulcers. This innovative therapy utilizes bio-identical basic fibroblast growth factor (bFGF) to transform wound healing in diabetic patients.

Diabetic ulcers present a significant and escalating challenge within the global healthcare system, affecting millions and often resulting in severe complications, including infections and amputations. ReGen Factor’s breakthrough therapy harnesses the power of bio-identical bFGF to enhance the body’s natural healing processes, offering a promising new solution for this critical condition.

Innovative Approach with Bio-Identical bFGF

ReGen Factor’s bio-identical bFGF technology mimics the naturally occurring growth factors in the human body, facilitating cellular proliferation, survival, migration, and differentiation. By introducing this bio-identical bFGF into the treatment of diabetic ulcers, ReGen Factor aims to stimulate rapid tissue regeneration and significantly improve healing outcomes.

“Our mission at ReGen Factor is to leverage advanced biotechnology to address some of the most pressing medical challenges,” said Stephen Blignaut, CEO and Managing Director of ReGen Factor. “The potential of our bio-identical bFGF to treat diabetic ulcers is immense, and we are committed to bringing this innovative treatment to patients in need. Seeking FDA approval is a pivotal step in this journey.”

Commitment to Rigorous Clinical Research

ReGen Factor has completed extensive preclinical studies demonstrating the safety and efficacy of their bio-identical bFGF in promoting wound healing. These promising results have paved the way for the initiation of clinical trials, which will be conducted in accordance with the highest regulatory standards to ensure the safety and effectiveness of the treatment.

Dr. Mukesh Kumar, Non-Executive Director at ReGen Factor and an expert in global regulatory project management, added, “Our comprehensive clinical development plan will provide robust data to support our FDA submission. We are dedicated to maintaining the highest standards of scientific rigor and patient safety throughout this process.”

Global Impact and Future Prospects

FDA approval of ReGen Factor’s bio-identical bFGF treatment for diabetic ulcers would mark a significant milestone in wound care and regenerative medicine. This innovative therapy has the potential to improve the quality of life for millions of diabetic patients worldwide, reducing the burden on healthcare systems and minimizing the risk of severe complications.

ReGen Factor is also exploring the application of their bio-identical bFGF technology in other medical areas, including heart disease, diabetic eye treatment, and neurodegenerative conditions such as dementia and Parkinson’s disease.

About ReGen Factor

ReGen Factor is a progressive R&D skin biology company based in Australia, with a global reach. Specializing in the development of bio-identical and cost-effective fibroblast growth factors, ReGen Factor is committed to making a global impact in the cosmetic, cosmeceutical, and pharmaceutical industries. Their flagship products, including PepFactor Skin and PepFactor Scalp, are at the forefront of non-surgical rejuvenation treatments, enhancing the anti-aging appearance of skin and promoting hair growth.

For more information about ReGen Factor and their innovative treatments, please visit www.regenfactor.org or contact:

Media Contact:

Claire Ironside
Public Relations Manager
ReGen Factor
Phone: +61 2 8916 6220
Email: info@pepfactor.org

Forward-Looking Statements

This press release contains forward-looking statements regarding ReGen Factor’s plans to seek FDA approval for its bio-identical bFGF treatment. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual outcomes to differ materially. ReGen Factor undertakes no obligation to update these forward-looking statements.

Disclaimer

This document contains forward-looking statements that are subject to risks and uncertainties. The effectiveness of Advanced Memory Factor has not been evaluated by regulatory authorities, and it is not intended to diagnose, treat, cure, or prevent any disease. ReGen Factor undertakes no obligation to update these statements.

For more information about ReGen Factor and their innovative treatments, please visit www.regenfactor.org or contact:

Claire Ironside
Public Relations Manager
ReGen Factor
Phone: +61 2 8916 6220
Email: info@pepfactor.org